化合物简介
Etretinate (trade name Tegison) is a medication developed by Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe psoriasis. It is a second-generation retinoid. It was subsequently removed from the Canadian market in 1996 and the United States market in 1998 due to the high risk of birth defects. It remains on the market in Japan as Tigason.
基本信息
中文名称
依曲替酯
英文名称
etretinate
中文别名
替维甲、阿维A酯、全反式-9-(4-甲氧基-2,3,6-三甲基苯基)-3,7-二甲基-2,4,6,8-壬四烯酸乙酯
英文别名
Etretinato、ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate、Etretinato [INN-Spanish]、Ro 10-9359、Etretinatum [INN-Latin]、ethyl (all-E)-9-(4-methyoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate、Retinoid、Etretinatum、ethyl all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate、Tegison、9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-1-oic acid ethyl ester、Ethyl etrinoate
CAS号
54350-48-0
分子式
C23H30O3
分子量
354.483
精确质量
354.219
PSA
35.53
LOGP
5.6455
编号系统
UNII
65M2UDR9AG
物化性质
外观与性状
结晶固体
密度
1.006g/cm3
沸点
506.4ºC at 760 mmHg
熔点
104-105ºC
闪点
219.4ºC
折射率
1.544
储存条件
Amber Vial, -20ºC Freezer
合成路线
